{"entity": "publication", "iuid": "31c151bf0c1f4d60b835522423c01b39", "timestamp": "2026-08-23T09:27:03.870Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/31c151bf0c1f4d60b835522423c01b39.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/31c151bf0c1f4d60b835522423c01b39"}}, "title": "Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of \u03b3\u03b4 T-cells.", "authors": [{"family": "Al Agrafi", "given": "Faisal", "initials": "F"}, {"family": "Gaballa", "given": "Ahmed", "initials": "A"}, {"family": "Hahn", "given": "Paula", "initials": "P"}, {"family": "Arruda", "given": "Lucas C M", "initials": "LCM"}, {"family": "Jaramillo", "given": "Adrian C", "initials": "AC"}, {"family": "Witsen", "given": "Maartje", "initials": "M"}, {"family": "Lehmann", "given": "S\u00f6ren", "initials": "S"}, {"family": "\u00d6nfelt", "given": "Bj\u00f6rn", "initials": "B"}, {"family": "Uhlin", "given": "Michael", "initials": "M"}, {"family": "Stikvoort", "given": "Arwen", "initials": "A", "orcid": "0000-0002-0251-5628", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/be030766d9964c6b8e563434c3e5e3b9.json"}}], "type": "journal article", "published": "2024-07-27", "journal": {"title": "Oncoimmunology", "issn": "2162-402X", "volume": "13", "issue": "1", "pages": "2379063", "issn-l": "2162-4011"}, "abstract": "Despite the considerable progress in acute myeloid leukemia (AML) treatment, relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is still frequent and associated with a poor prognosis. Relapse has been shown to be correlated with an incomplete eradication of CD34+ leukemic stem cells prior to HSCT. Previously, we have shown that a novel CD34-directed, bispecific T-cell engager (BTE) can efficiently redirect the T-cell effector function toward cancer cells, thus eliminating leukemic cells in vitro and in vivo. However, its impact on \u03b3\u03b4 T-cells is still unclear. In this study, we tested the efficacy of the CD34-specific BTE using in vitro expanded \u03b3\u03b4 T-cells as effectors. We showed that the BTEs bind to \u03b3\u03b4 T-cells and CD34+ leukemic cell lines and induce target cell killing in a dose-dependent manner. Additionally, \u03b3\u03b4 T-cell mediated killing was found to be superior to \u03b1\u03b2 T-cell mediated cytotoxicity. Furthermore, we observed that only in the presence of BTE the \u03b3\u03b4 T-cells induced primary AML blast killing in vitro. Importantly, our results show that \u03b3\u03b4 T-cells did not target the healthy CD34intermediate endothelial blood-brain barrier cell line (hCMEC/D3) nor lysed CD34+ HSCs from healthy bone marrow samples.", "doi": "10.1080/2162402X.2024.2379063", "pmid": "39076247", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11285226"}, {"db": "pii", "key": "2379063"}], "notes": [], "created": "2026-08-20T09:37:37.246Z", "modified": "2026-08-21T09:28:26.623Z"}